Group (n) | Age | Male/Female | Anti-LeishmaniaIgG (O.D.) | Lympho-proliferation (cpm)b | IFN-γ (pg/ml)b |
---|---|---|---|---|---|
Urban controls (10) | 24.9 (2.0) | 7/3 | < cut-off | < 100 | < 20 |
Endemic controls (15) | 28.7 (8.8) | 3/12 | < cut-offa | ND | < 20 |
LCL0 (14) | 28.4 (12.7) | 10/4 | 0.178 (0.073) | 2737 (1178) | 612 (207) |
LCL3 (7) | 28.5 (11.2) | 5/2 | 0.074 (0.021) | ND | 685 (348) |
ML (7) | 44.4 (11.9) | 5/2 | 0.016 (0.005) | > 5000 | > 2000 |
VL (10) | 18.4 (3.8) | 6/4 | 0.188 (0.072) | < 100 | < 20 |